Compare BridgeBio Pharma Inc (BBIO) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Innovative Industrial Properties Inc — how do they compare? BridgeBio Pharma Inc trades at $83.27 (market cap $16.46B), while Innovative Industrial Properties Inc trades at $63.7 (market cap $1.85B). The key difference: BridgeBio Pharma Inc is far larger — about 8.9× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 11.93% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | IIPR | |
|---|---|---|
Market Cap | $16.46B | $1.85B |
Sector | Health | Real Estate |
52-Week High | $90.17 | $64.44 |
52-Week Low | $44.81 | $44.58 |
Enterprise Value | $18.02B | $2.23B |
Dividend Yield | — | 11.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
IIPR trades at $63.78, down 1.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 but missing in Q1 2026, with revenue declining to $266M in 2025. Recent news highlights successful debt management, including repaying $282M in senior notes and issuing new debt, while cannabis rescheduling progress offers regulatory tailwinds.
The outlook for IIPR balances a high dividend yield and improved balance sheet against revenue declines and tenant risks. Investment opportunities include potential re-rating from regulatory changes and stable cash flows, but risks involve sector volatility and earnings inconsistency. Analyst sentiment is mixed with a Hold consensus, reflecting cautious optimism amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
